Research involving 147 patients with HCC (Hepatocellular Carcinoma) indicated that those exhibiting inactive TGF-β signaling pathways experienced reduced survival times in contrast to individuals with active TGF-β signaling. Here, TGFB1 is linked to hepatocellular carcinoma.